Xeris Biopharma Inc. (XERS)
NASDAQ: XERS
· Real-Time Price · USD
8.13
0.28 (3.57%)
At close: Sep 26, 2025, 1:13 PM
Xeris Biopharma Revenue Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Keveyis Revenue | 11.48M | 11.43M | 24.25M | 12.19M | 13.13M | 13.09M | 40.91M | 15.87M | 14.09M | 12.76M | 13.8M | 13.37M | 12.81M |
| Keveyis Revenue Growth | +0.51% | -52.88% | +98.90% | -7.12% | +0.33% | -68.01% | +157.84% | +12.61% | +10.45% | -7.58% | +3.22% | +4.36% | n/a |
| Product Revenue | 67.71M | 57.8M | 103.51M | 52.86M | 46.51M | 40.26M | 111.67M | 41.7M | 36.89M | 32.27M | 32.54M | 29.55M | 25.26M |
| Product Revenue Growth | +17.14% | -44.16% | +95.82% | +13.65% | +15.52% | -63.94% | +167.81% | +13.02% | +14.34% | -0.84% | +10.10% | +17.00% | n/a |
| Product, Other Revenue | 1.31M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Product, Other Revenue Growth | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expense Breakdown
| Period Ending | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 44.39M | 44.02M | 40.14M | 44.97M | 39.99M | 38.38M | 37.57M | 37.29M | 37.63M | 33.6M | 34.36M | 34.49M | 32.98M | 35.91M | 54.18M | 26.54M | 25.93M | 19.08M | 18M | 16.48M | 17.64M | 21.61M | 20.64M | 14.88M | 15.02M | 12.52M | 8.72M | 4.65M | 4.5M | 3.24M | 3.1M | 2.02M | 1.56M | 1.34M |
| Selling, General, and Administrative Revenue Growth | +0.85% | +9.66% | -10.74% | +12.44% | +4.20% | +2.16% | +0.75% | -0.92% | +11.99% | -2.19% | -0.39% | +4.57% | -8.16% | -33.71% | +104.18% | +2.35% | +35.91% | +6.00% | +9.18% | -6.57% | -18.34% | +4.67% | +38.75% | -0.98% | +20.02% | +43.47% | +87.63% | +3.36% | +38.90% | +4.55% | +53.59% | +29.38% | +16.26% | n/a |
| Research and Development Revenue | 8.05M | 7.75M | 6.09M | 5.89M | 5.76M | 7.82M | 6.38M | 5.03M | 6.09M | 4.84M | 4.96M | 6.04M | 3.72M | 6.25M | 10.08M | 5.66M | 5.38M | 4.03M | 5.11M | 3.88M | 5.29M | 6.65M | 12.42M | 15.52M | 19.33M | 13.17M | 12.39M | 10.88M | 8.68M | 8.71M | 6.58M | 5.72M | 4.2M | 3.66M |
| Research and Development Revenue Growth | +3.90% | +27.27% | +3.46% | +2.24% | -26.36% | +22.55% | +26.78% | -17.30% | +25.82% | -2.36% | -18.00% | +62.53% | -40.51% | -38.01% | +78.03% | +5.20% | +33.51% | -21.10% | +31.84% | -26.72% | -20.42% | -46.49% | -19.96% | -19.73% | +46.83% | +6.27% | +13.93% | +25.33% | -0.40% | +32.44% | +14.90% | +36.28% | +14.72% | n/a |